Acyl-sulfamates Target the Essential Glycerol-Phosphate Acyltransferase (PlsY) in Gram-Positive Bacteria
PlsY is the essential first step in membrane phospholipid synthesis of Gram-positive pathogens. PlsY catalyzes the transfer of the fatty acid from acyl-phosphate to the 1-position of glycerol-3-phosphate to form the first intermediate in membrane biogenesis. A series of non-metabolizable, acyl-sulfamate analogs of the acyl-phosphate PlsY substrate were prepared and evaluated as inhibitors of Staphylococcus aureus PlsY and for their Gram-positive antibacterial activities. From this series phenyl (8-phenyloctanoyl) sulfamate had the best overall profile, selectively inhibiting S. aureus phospholipid biosynthesis and causing the accumulation of both long-chain fatty acids and acyl-acyl carrier protein intermediates demonstrating that PlsY was the primary cellular target. Bacillus anthracis was unique in being more potently inhibited by long chain acyl-sulfamates than other bacterial species. However, it is shown that Bacillus anthracis PlsY is not more sensitive to the acyl-sulfamates than S. aureus PlsY. Metabolic profiling showed that B. anthracis growth inhibition by the acyl-sulfamates was not specific for lipid synthesis illustrating that the amphipathic acyl-sulfamates can also have off-target effects in Gram-positive bacteria. Nonetheless, this study further advances PlsY as a druggable target for the development of novel antibacterial therapeutics, through the discovery and validation of the probe compound phenyl (8-phenyloctanoyl) sulfamate as a S. aureus PlsY inhibitor.
INTRODUCTION<!>Chemistry<!>SAR of acyl-sulfamates against S. aureus PlsY<!>Antimicrobial activity<!>Target validation<!>Mode of action in B. anthracis<!>CONCLUSIONS<!>General synthetic methods<!>General procedure for the synthesis of palmitoylsulfamates (1\xe2\x80\x9321)<!>Methyl palmitoylsulfamate (1)<!>Cyclopentyl palmitoylsulfamate (2)<!>Tetrahydrofuran-3-yl palmitoylsulfamate (3)<!>Cyclohexyl palmitoylsulfamate (4)<!>Tetrahydro-2H-pyran-4-yl palmitoylsulfamate (5)<!>Piperidin-4-yl palmitoylsulfamate (6)<!>tert-butyl 4-(N-palmitoylsulfamoyloxy)piperidine-1-carboxylate (7)<!>Phenyl palmitoylsulfamate (8)<!>4-chlorophenyl palmitoylsulfamate (9)<!>3-chlorophenyl palmitoylsulfamate (10)<!>3,4 - dichlorophenyl palmitoylsulfamate (11)<!>p-tolyl palmitoylsulfamate (12)<!>4-methoxyphenyl palmitoylsulfamate (13)<!>Methyl 2-(4-(N-palmitoylsulfamoyloxy)phenyl)acetate (14)<!>Ethyl 4-(N-palmitoylsulfamoyloxy)benzoate (15)<!>4-(2-aminoethyl)phenyl palmitoylsulfamate (16)<!>4-(2-(tert-butoxycarbonylamino)ethyl)phenyl palmitoylsulfamate (17)<!>4\'-nitrobiphenyl-4-yl palmitoylsulfamate (18)<!>Benzo[d][1,3]dioxol-5-yl palmitoylsulfamate (19)<!>Quinolin-6-yl palmitoylsulfamate (20)<!>3-(sulfamoyloxy)benzofuran-6-yl palmitoylsulfamate (21)<!>General procedure for the synthesis of 22\xe2\x80\x9328<!>4-methoxyphenyl tetradecanoylsulfamate (22)<!>4-methoxyphenyl undec-10-enoylsulfamate (23)<!>Phenyl (11-phenylundecanoyl) sulfamate (24)<!>Phenyl (8-phenyloctanoyl) sulfamate (25)<!>Phenyl (7-phenylheptanoyl) sulfamate (26)<!>Phenyl (6-phenylhexanoyl) sulfamate (27)<!>(E)-Phenyl 3-(biphenyl-4-yl)acryloylsulfamate (28)<!>Membrane preparation and PlsY assay<!>MIC determinations<!>Acetate labeling<!>Pathway Labeling<!>ACP immunoblotting<!>Gas chromatography and mass spectrometry<!>
<p>The creeping rise in antibacterial drug resistance combined with the failure of current discovery programs to produce new antibacterial targets and lead compounds to meet this growing threat is of great concern to the whole medical community.1 This comes at a time when increasingly virulent and resistant strains of bacteria such as methicillin resistant Staphylococcus aureus (MRSA) lineage USA300 are becoming dominant in our clinics causing much morbidity and mortality. Current efforts at developing new Gram-positive antibacterial agents are largely focused around standard antibacterial classes including β-lactams, oxazolidinones and fluoroquinolones for which class specific resistance mechanisms preexist.2 Thus, there is an urgent need to develop new therapeutic targets that are essential for cell viability and suitable for therapeutic intervention.</p><p>One such alternative target is the recently discovered PlsX and PlsY mediated phospholipid biosynthetic pathway.3 PlsX catalyzes the formation of acyl-PO4 from the acyl-acyl carrier protein (ACP) end-products of fatty acid biosynthesis. PlsY transfers the acyl group from acyl-PO4 to the 1-position of glycerol-PO4 to form the first intermediate in membrane phospholipid synthesis. Targeting this pathway appears desirable because it is essential in all significant Gram-positive human pathogens3 and disrupting bacterial membrane biogenesis is a proven strategy for the development of potent antibacterials.4 Furthermore, humans synthesize the phospholipids using acyl-CoA-dependent glycerol-PO4 acyltransferases and PlsY homologs are not found in mammalian genomes. Despite these clear advantages, targeting PlsY presents challenges. PlsY is a small (23 kDa) integral membrane protein with 5 transmembrane helicies.5 Although the residues critical for catalysis are known, structural information is not available and the enzyme is most active in its native membrane environment. Thus, our first approach to inhibitor design was to synthesize five classes of nonhydrolyzable acyl-PO4-based bioisosteric inhibitors of PlsY.6 These chemical classes included acyl-phosphonates, acyl-phosphoramides, reverse amide phosphonates, acyl-sulfamates and acyl-sulfamides (Fig. 1). The most active inhibitors from each series generally contained a long aliphatic chain that mimicked the acyl-PO4 substrate of PlsY. These PlsY inhibitors displayed weak to moderate antimicrobial activity against a representative panel of Gram-positive bacteria, with the exception of Bacillus anthracis, for which potent antibacterial activity was observed.</p><p>This study expands the SAR and mechanism of action within the acyl-sulfamate class (Fig.1), the most potent of the bioisosteric PlsY inhibitors.6 The acyl-sulfamate scaffold was modified at the R1 (head) and R2 (tail) positions (Scheme 1) to determine the effect of substitutions on the potency against PlsY and antimicrobial activity. Biochemical analysis of acyl-sulfamate treated cells confirmed that these molecules target the PlsY pathway for phospholipid synthesis, although these amphipathic molecules can also exhibit off-target activities, which need to be carefully monitored to gain a clear understanding of antibacterial structure activity relationships.</p><!><p>The acyl-sulfamates were synthesized as described previously.6 Briefly, chlorosulfonyl isocyanate was treated with neat formic acid to generate sulfamoyl chloride that was reacted with various alcohols to synthesize a series of sulfamates introducing the R1 substitution. Acylation of the sulfamates with selected acyl chlorides provided the desired acylsulfamates introducing the R2 acyl tail (Scheme 1).</p><!><p>The SAR at the acyl-PO4 R1 head site (Scheme 1) was explored by the synthesis of compounds 1–21 (Table 1) that maintained a palmitoyl (C16) chain at the R2 tail position to mimic the natural substrate. The potency of these acyl-sulfamates as PlsY inhibitors was influenced by the size of the R1 substituent with the larger six membered and bicyclic analogs being generally more potent than the smaller furan (3), cyclopentane (2) and methyl (1) analogs. The potency was also influenced by the hydrophobicity of the R1 substituent. The more hydrophobic cyclohexane analog 4 was six-fold more potent than the 4-oxygen containing pyran analog 5 and at least twenty-fold more potent than the 4-NH containing piperidine analog 6. The considerable loss of potency of 6 suggested that a free amine was not tolerated at this site due to a site specific interaction and a potentially strong desolvation penalty of this cation. This was further corroborated by the significant restoration of potency upon protection of the 4-NH of piperidine (6) with a Boc-group (7). Replacing the saturated and comparatively flexible cyclohexane with an aromatic phenyl group (8) led to a minor loss in potency; nevertheless, the availability of various substituted phenols made it the better option for further exploring this site. A 4-Cl substituent on the phenyl ring (9) proved to be somewhat better than the unsubstituted 8. The 3, 4-dichloro analog 11 and the 3-chloro analog 10 were less potent than 9 suggesting that the 4-position on the phenyl was the preferred site for further exploration. We replaced the 4-Cl with substituents of increasing size including methyl (12), hydroxymethyl (13) methyl propionate (14), ethyl acetate (15) and 4-(4-NO2) biphenyl (18). Despite the substantial increase in size at the 4-position, the potency was only two-fold or less compared to 9. The only 4-substitutent from our series that did show a significant loss of potency was the 4-ethylamine analog 16. This loss was attributed to the presence of the free amine also found in 16 rather than the size because potency was restored in the Boc-protected analog 17. This trend was similar to the preceding amine containing pair (6 & 7). We also synthesized bicyclic analogs 19–21 and found that the benzodioxole (19) and quinoline (20) derivatives had potencies similar to most of the 4-substituted phenols while the benzofuranyl 3-sulfamate (21) was four-fold less potent.</p><p>The SAR at R2 acyl tail position (Scheme 1) was explored by synthesizing derivatives 22–28 that incorporated a phenyl or 4-OCH3 phenyl at R1 head (Table 2). The myristoyl (C14) derivative 22 was slightly better than the C16 derivative 13 while further decreasing the chain length to C11 in 23 led to a three-fold decrease in potency. Interestingly, a terminal phenyl on the C11 aliphatic chain (24) at R2 was well-tolerated and the compound was equipotent to the palmitoyl analog 8. Further decreasing the chain length between the terminal phenyl and the head group to C8 (25) led to a three-fold decrease in potency while the shorter C7 (26) and C6 (27) analogs and the cinnamic acid analog (28) were at least ten-fold less potent than 24. Thus, for the compound series 24–28, the potency was directly related to the alkyl chain length at R2.</p><!><p>The synthesized compounds were screened against a representative panel of Gram-positive bacteria including 22 virulent strains of B. anthracis (Tables 1 and 2). Palmitoyl (C16) analogs that were modified at the R1 position (1 – 21) and found to be inactive against S. aureus PlsY (1, 2, 6 and 16) were, in general, inactive against our panel of Gram-positive bacteria (Table 1). In contrast to their S. aureus PlsY inhibitory activity, most of the palmitoyl analogs were inactive against S. aureus in the whole cell assay (Table 1) indicating that additional factors including permeability may be influencing the whole cell activity of these compounds. Exceptions in this case were compounds 15 and 13, which had low MIC of 6.25 µg/ml and 12.5µg/ml respectively against S. aureus. Interestingly, most of the palmitoyl analogs were highly active against E. faecalis and B. anthracis; however, the MIC values of these compounds were considerably lower than the corresponding PlsY IC50 suggesting that this class of molecules can affect bacterial growth by a non-PlsY mechanism (Table 1). Most of these analogs were generally inactive against S. pneumoniae and B. subtilis except for 13 which displayed good activity against both (Table 1).</p><p>For compounds incorporating a 4-OCH3 phenyl at the R1 position, shortening the chain length at R2 from C16 (13) to C14 (22) led to significant loss of activity against S. pneumoniae, S. aureus and B. subtilis but caused a slight improvement in activity against E. feacalis and B. anthracis (Table 2). Further decreasing the chain length to C11 (23) led to significant restoration of the S. aureus and B. subtilis activity, further improvement in the E. faecalis activity and a modest decreasing in the B. anthracis activity. Thus 23 displayed a broad antimicrobial profile with good activity against multiple species in our panel of Gram-positive bacteria.</p><p>For compounds 24–27 that incorporated a phenyl group at the R1 position and a terminal phenyl group on the R2 acyl chain, decreasing the chain length between the head group and the terminal phenyl at R2 led to a proportional decrease in the S.aureus inhibitory activity, in similar fashion to their PlsY inhibitory activity (Table 2). The MIC values of 24 – 27 against S. aureus are comparable to their PlsY IC50. A similar trend of increasing MIC with decreasing chain length in 24 – 27 is also observed for B. anthracis (Table 2). Compounds 24–27 were generally inactive against S. pneumoniae and B. subtilis. The cinnamic acid analog 28 showed moderate to weak activity against S. aureus and E. faecalis but was generally inactive against the other species (Table 2).</p><!><p>Whether the antibacterial effects of the acyl-sulfamates were due to PlsY inhibition was addressed in a series of metabolic labeling and structural studies. The phenyl (8-phenyloctanoyl) sulfamate 25 was selected for this purpose based on its reasonable PlsY inhibition, good antimicrobial activity against S. aureus and B.anthracis and comparatively lower molecular weight. Two genetic systems provided the template for assessing the physiological changes that occur after PlsY inhibition. One is in Bacillus subtilis where the plsY gene was silenced7 and the second is the gpsA mutant of S. aureus that conditionally deprives the cells of the glycerol-PO4 for PlsY.8,9 Lipid synthesis inhibitors do not cause cell lysis or immediate growth cessation. Rather, bacteria continue to grow for a few generations until the imbalance between membrane lipid and protein synthesis becomes intolerable and the cells cease proliferation.10
S. aureus cell growth did not immediately cease following the addition of 25, but slowed down over approximately 2 h before stopping completely when treated with 25 µM or greater of 25 (Fig. 2A). This gradual stop to S. aureus cell growth was reminiscent of the gpsA mutants deprived of glycerol and PlsY knockdown cells.8,9 Metabolic labeling in the presence and absence of 50 µM 25 was used to assess its effect on the four major pathways of macromolecular biosynthesis (Fig. 2B). Compound 25 selectively inhibited lipid biosynthesis compared to the other major macromolecules. Accordingly, 25 caused a concentration dependent decrease in [14C] acetate incorporation into fatty acids and membrane phospholipids (Fig. 2C). In the Bacillus subtilis PlsY conditional gene knockout model, knocking out PlsY causes accumulation of intracellular free fatty acids.7 An increase in 14C-labeled free fatty acids was also observed in 25 treated cells (not shown), consistent with PlsY inhibition as the in vivo mode of action for 25 against S. aureus.</p><p>Another metabolic defect associated with a PlsY inhibitor was an increase in the average chain-length of fatty acids in treated cells. The chain-length of membrane fatty acids was determined by the competition between the elongation condensing enzyme (FabF) and the glycerol-PO4 acyltransferase.11 If the acyltransferase was inhibited, then FabF has a competitive advantage and the acyl-ACP end-product undergo additional rounds of elongation leading to an increase in the average chain length in the membrane phospholipids. The major fatty acids in control (DMSO-treated) strain RN4220 were 15:0 and 17:0 with only small amounts of 19:0 and 20:0 chain lengths (Table 3). Treatment with increasing amounts of 25 led to a progressive increase in the chain length of fatty acids produced by the cells. For example, 21-carbon fatty acids were not detected in untreated strain RN4220, but comprised 14% of the total fatty acids in S. aureus treated with 50 µM 25. The appearance of these longer chain lengths correlated with a decrease in the 15-carbon fatty acids. Phosphatidylglycerol (PtdGro) was the major membrane phospholipid in S. aureus, and mass spectrometry was used to determine how the distribution of PtdGro molecular species was impacted by treatment with 25. In untreated cells, the major molecular species was the 32-carbon PtdGro consisting of 17:0 in the 1-position and 15:0 in the 2-position (Fig. 3A).10 In cells treated with 25 µM 25, the principle molecular species contained 34 carbons, and in cells treated with 50 µM 25, 35-carbon PtdGro was the most abundant species (Fig. 3B). A 36-carbon molecular species was a major component in cells treated with 50 µM 25, but was barely detected in untreated cells (Fig. 3C). An increase in the average chain-length of fatty acids in membrane phospholipids was a hallmark feature that points to the acyl-sulfamates targeting PlsY in vivo.</p><p>A blockade at the glycerol-PO4 acyltransferase step should also lead to the accumulation of long chain acyl-ACP, which continues to be produced by the fatty acid biosynthetic pathway, but fails to be utilized due to the block in phospholipid synthesis.12 Therefore, we examined the composition of the ACP pool in S. aureus strain RN4220 treated with various concentrations of 25 (Fig. 4). Acyl-ACPs can be separated by urea gel electrophoresis based on the hydrophobicity of the attached acyl chain13, and were detected by western blotting using anti-ACP antibody.14 The ACP pool in untreated cells was primarily non-esterified ACP. Treatment with 25 led to a significant increase in the level of long-chain acyl-ACP in the cells, indicating a block in the utilization of the end products of fatty acid synthesis as acyltransferase substrates. These measurements of the intracellular ACP pool composition strongly support the conclusion that PlsY was a target for 25 in S. aureus.</p><!><p>There are three PlsY homologs in B. anthracis. BaPlsY1 and BaPlsY2 have reasonable homology to the SaPlsY (~43–45% identity). BaPlsY3 has a much lower homology (28% identity). We reconstituted the enzymatic activity of all three BaPlsY. BaPlsY3 has no detected acyltransferase activity. BaPlsY2 has lower acyltransferase activity, while BaPlsY1 has the most acyltransferase activity. Based on bioinformatics predication and enzyme activity from reconstitution, we believe that BaPlsY1 is the major PlsY in Bacillus anthracis, and therefore choose that for compound activity testing. Many PlsY inhibitors had more potent antibacterial activity against B. anthracis compared to other Gram-positive bacteria (Tables 1 and 2). These lower MICs in B. anthracis suggested that either the PlsY of this organism was more sensitive to the acyl-sulfamates than the S. aureus enzyme, or that the acyl-sulfamates also have an off-target effect on B. anthracis growth. The first possibility was tested by cloning and expressing the B. anthracis PlsY1, and determining the IC50 for the prototypical acyl-sulfamate, 25 (Fig. 5A). The 2-fold increase in the potency of 25 against B. anthracis PlsY1 was about the same as the difference between the MIC for S. aureus and the average MIC for the wild-type B. anthracis strain panel (Table 2). However, the effect of 25 on the growth of B. anthracis Sterne was also not characteristic of lipid synthesis inhibitors (Fig. 5B). Compound 25 addition caused an abrupt cessation of cell growth that was more indicative of a membrane disruptive agent as opposed to specific inhibition of membrane biogenesis. Furthermore, the acyl-sulfamates inhibited protein, DNA and RNA synthesis in B. anthracis Sterne (not shown) compared to their selective effect on lipid synthesis observed in S. aureus. An important caveat to these experiments was that we cannot determine if the sensitivity of B. anthracis Sterne vaccine strain is due to the loss of the pXO2 plasmid that produces a protective capsule, which may allow the acyl-sulfamates to target the cell membrane. Nonetheless, these data suggest that the acyl-sulfamates may have off-target effects on bacterial membrane function in some bacteria.</p><!><p>As part of our SAR study, a series of acyl-sulfamates with modifications at the R1 head and R2 acyl tail positions were synthesized and evaluated as S. aureus PlsY inhibitors and for Gram-positive antibacterial activities. At the R1 position, a wide range of substituents were tolerated (1 – 21) with the exception of substituents containing a free amine (6, 16) that led to significant loss of PlsY activity. At R2, the acyl chain could be shortened from C16 to C11 with minimal loss of PlsY activity (13 vs. 22, 23) and compounds incorporating a terminal phenyl on the acyl chain (24–27) displayed a direct correlation between chain length and PlsY inhibitory activity. The acyl-sulfamates, typified by 25, possessed antibacterial activity through the inhibition of PlsY in vivo. Compound 25 caused a slow inhibition of S. aureus growth that was characteristic of other lipid biosynthesis inhibitors. Compound 25 selectively inhibited lipid synthesis compared to other major branches of macromolecular biosynthesis, caused an increase in the average chain-length of membrane phospholipid fatty acids and triggered the accumulation of long-chain acyl-ACP end-products of fatty acid synthesis. All of these metabolic effects are consistent with PlsY inhibition as the ultimate cellular target. A potential drawback to this series of compounds was revealed by the analysis of the acyl-sulfamate series against B. anthracis Sterne. In this system, the amphipathic acyl-sulfamate possessed significant off-target effects on B. anthracis metabolism and caused the immediate cessation of bacterial growth that is not observed in S. aureus. Nonetheless, the analysis of the acyl-sulfamate class further advances PlsY as a druggable target for the development of novel antibacterial therapeutics. Future development of the acyl-sulfamate compound series will include finding suitable molecular replacements for the long aliphatic chain at position R2 (Scheme 1) that will retain PlsY activity and have improved drug-like properties and less off-target activity.</p><!><p>All reagents and solvents were purchased from commercial sources. All reactions were performed under inert atmosphere. The final reaction mixtures were purified on Isolera Flash Purification System using high performance SNAP columns from Biotage. The solvent system used for all purifications was hexane/ethyl acetate (5–100% gradient). The purity and mass of the synthesized compounds were determined on a Waters ACQUITY UPLC-PDA-ELSD-MS system using a C18 reverse phase column and 0.1% formic acid/water - 0.1% formic acid/acetonitrile binary solvent system. All synthesized compounds were at least 95% pure. The structures of the synthesized compounds were confirmed by 1H NMR which was recorded on a 400Mhz Varian AVANCE 400-FT NMR.</p><!><p>Formic acid (98%, 2 eq) was added drop-wise to chlorosulfonyl isocyanate (2 eq) at 0°C. The mixture was allowed to rise to room temperature and stirred until the gas evolution stopped (~2 h). The desired alcohol (1 eq) in dimethylacetamide (DMA) was added drop-wise to the resulting sulfamoyl chloride at 0°C. The mixture was stirred at 0°C for 10 min and then at room temperature for 3 h. The mixture was then poured into cold brine and extracted with EtOAc. The combined extracts were washed with brine, dried over Na2SO4 and concentrated in vacuo to provide the desired sulfamate ester which was used directly in the next step.</p><p>To a mixture of the obtained sulfamate ester (1 eq), triethylamine (3 eq) and N, N-dimethylpyridin-4-amine [DMAP] (0.1 eq) in anhydrous DCM:DMF (1:1) at 0°C were added palmitoyl chloride (1 eq). The mixture was stirred at 0°C for 10 min and then at room temperature overnight. The reaction mixture was diluted with DCM and washed with 2.5% HCl, water and brine, dried over Na2SO4 and concentrated in vacuo. The crude mixture was separated by column chromatography as described above.</p><!><p>Synthesized with methanol. Yield = 17%. 1H NMR (400 MHz, CDCl3) δ 7.95 (br-s, 1H), 4.06 (s, 3H), 2.39 (t, J = 7.5 Hz, 2H), 1.66 (p, J = 7.5 Hz, 2H), 1.25 (br-s, 24H), 0.88 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 348.22 [M-H]−</p><!><p>Synthesized with cyclopentanol. Yield = 9%. 1H NMR (400 MHz, CDCl3) δ 8.00 (br-s, 1H), 5.38 (m, 1H), 2.41 (t, J = 7.3 Hz, 2H), 2.10–1.75 (m, 6H), 1.74–1.58 (m, 4H), 1.27 (br-s, 24H), 0.90 (t, J = 5.9 Hz, 3H). MS-ESI m/z = 402.48 [M-H]−</p><!><p>Synthesized with tetrahydrofuran-3-ol. Yield = 50%. 1H NMR (400 MHz, CDCl3) δ 7.98 (br-s, 1H), 5.59 (t, J = 5.0 Hz, 1H), 4.10–3.79 (m, 5H), 2.36 (t, J = 7.5 Hz, 2H), 2.30–2.16 (m, 2H), 1.74–1.61 (m, 3H), 1.26 (br-s, 21H), 0.88 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 404.31 [M-H]−</p><!><p>Synthesized with cyclohexanol. Yield = 75%. 1H NMR (400 MHz, CDCl3) δ 7.99 (br-s, 1H), 4.90 (dt, J = 8.9, 4.8 Hz, 2H), 2.38 (t, J = 6.9, 6.4 Hz, 3H), 2.03–1.93 (m, 2H), 1.83–1.73 (m, 2H), 1.73–1.47 (m, 6H), 1.47–1.15 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 416.29 [M-H]−</p><!><p>Synthesized with tetrahydro-2H-pyran-4-ol. Yield = 63%. 1H NMR (400 MHz, CDCl3) δ 8.04 (br-s, 1H), 5.22–5.13 (m, 1H), 4.02–3.90 (m, 2H), 3.59 (ddd, J = 11.7, 8.5, 3.2 Hz, 2H), 2.38 (t, J = 7.5 Hz, 2H), 213–2.04 (m, 2H), 1.97–1.86 (m, 2H), 1.68 (p, J = 7.3 Hz, 2H), 1.28 (s, 24H), 0.90 (t, J = 6.6 Hz, 3H). MS-ESI m/z = 418.43 [M-H]−</p><!><p>Compound (7) was stirred in a 10% solution of Trifluoroacetic acid in DCM for 30mins and the solvent evaporated to afford (6). 1H NMR (400 MHz, CDCl3) δ 5.16–5.04 (m, 1H), 3.34–3.16 (m, 4H), 2.35–2.24 (m, 1H), 2.24–2.06 (m, 3H), 1.62 (p, J = 7.9 Hz, 2H), 1.25 (br-s, 24H), 0.88 (t, J = 5.7 Hz, 2H). MS-ESI m/z = 417.42 [M-H]−</p><!><p>Synthesized with t-butyl 4-hydroxypiperidine-1-carboxylate. Yield = 38%. 1H NMR (400 MHz, CDCl3) δ 8.49 (br-s, 1H), 5.21–5.06 (m, 1H), 3.72–3.61 (m, 2H), 3.42–3.32 (m, 4.6 Hz, 2H), 2.39 (t, J = 6.5 Hz, 2H), 2.03–1.92 (m, 2H), 1.92–1.80 (m, 2H), 1.75–1.59 (m, 2H), 1.48 (s, 9H), 1.28 (br-s, 24H), 0.90 (t, J = 5.9 Hz, 3H). MS-ESI m/z = 517.38 [M-H]−</p><!><p>Synthesized with phenol. Yield = 70%. 1H NMR (400 MHz, CDCl3) δ 7.87 (br-s, 1H), 7.47–7.27 (m, 5H), 2.40 (t, J = 7.5 Hz, 2H), 1.75–1.46 (m, 2H), 1.26 (br-s, 24H), 0.88 (t, J = 6.3 Hz, 3H). MS-ESI m/z = 410.73 [M-H]−</p><!><p>Synthesized with 4-chlorophenol. Yield = 63%. 1H NMR (400 MHz, CDCl3) δ 7.84 (br-s, 1H), 7.38 (d, 8.3 Hz, 2H), 7.25 (d, J = 9.1 Hz, 2H), 2.40 (t, J = 7.4 Hz, 2H), 1.64 (q, J = 7.3 Hz, 2H), 1.26 (br-s, 24H), 0.88 (t, J = 6.7 Hz, 3H). MS-ESI m/z = 444.55 [M-H]−</p><!><p>Synthesized with 3-chlorophenol. Yield = 33%. 1H NMR (400 MHz, CDCl3) δ 7.40–7.30 (m, 3H), 7.21 (dt, J = 6.8, 2.3 Hz, 1H), 2.39 (t, J = 7.4 Hz, 2H), 1.79–1.50 (m, 2H), 1.25 (br-s, 24H), 0.88 (t, J = 6.7 Hz, 3H). MS-ESI m/z = 444.20 [M-H]−</p><!><p>Synthesized with 3, 4-dichlorophenol. Yield = 32%. 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 7.5 Hz, 1H), 7.44 (d, J = 7.4 Hz, 1H), 7.20 (d, J = 7.18 Hz, 1H), 2.39 (t, J = 7.4 Hz, 1H), 1.78–1.46 (m, 1H), 1.25 (br-s, 24H), 0.88 (t, 6.5 Hz, 3H). MS-ESI m/z = 478.16 [M-H]−</p><!><p>Synthesized with p-cresol. Yield = 65%. 1H NMR (400 MHz, CDCl3) δ 7.18 (q, J = 8.7 Hz, 4H), 2.50–2. 23 (m, 3H), 1.69–1.57 (m, 2H), 1.26 (br-s, 24H), 0.88 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 424.29 [M-H]−</p><!><p>Synthesized with 4-methoxyphenol. Yield = 85%. 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 9.2 Hz, 2H), 6.90 (d, J = 9.2 Hz, 2H), 3.81 (s, 2H), 2.40 (t, J = 7.5 Hz, 2H), 1.65 (dt, J = 14.6, 7.4 Hz, 2H), 1.26 (br-s, 24H), 0.88 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 440.23 [M-H]−</p><!><p>Synthesized with methyl 2-(4-hydroxyphenol)acetate. Yield = 41%. 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 3.71 (s, 3H), 3.64 (s, 2H), 2.39 (t, J = 7.5 Hz, 2H), 1.65 (dt, J = 14.9, 7.4 Hz, 2H), 1.26 (br-s, 24H), 0.88 (t, J = 6.8 Hz, 2H). MS-ESI m/z = 482.32 [M-H]−</p><!><p>Synthesized with ethyl 4-hydroxybenzoate. Yield = 51%. 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.8 Hz, 2H), 4.39 (q, J = 7.1 Hz, 2H), 2.40 (t, J = 7.4 Hz, 2H), 1.69–1.60 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.25 (br-s, 24H), 0.88 (t, J = 5.8 Hz, 3H). MS-ESI m/z = 482.42 [M-H]−</p><!><p>Compound (17) was stirred in neat Trifluoroacetic acid (TFA) for 12hrs. The TFA was evaporated and the crude mixture dissolved in minimal amount of acetone. The product was precipitated by addition of water and then filtered and dried under vacuum to provide (16) in 37% yield. 1H NMR (400 MHz, DMSO) δ 7.76 (br-s, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.3 Hz, 2H), 3.13–2.92 (m, 2H), 2.89–2.71 (m, 2H), 1.95 (t, J = 7.4 Hz, 3H), 1.48–1.34 (m, 4H), 1.24 (s, 24H), 0.86 (t, J = 6.6 Hz, 3H). MS-ESI m/z = 453.17 [M-H]−</p><!><p>Synthesized with t-butyl 4-hydroxyphenethylcarbamate. Yield = 54%. 1H NMR (400 MHz, DMSO) δ 7.30 (d, J = 8.5 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 3.13 (q, J = 6.5 Hz, 2H), 2.71 (t, J = 7.5 Hz, 2H), 2.26 (t, J = 7.2 Hz, 2H), 1.49 (dt, J = 12.5, 5.7 Hz, 2H), 1.24 (br-s, 24H), 0.86 (t, J = 6.5 Hz 3>H). MS-ESI m/z = 553.29 [M-H]−</p><!><p>Synthesized with 4'-nitrobiphenyl-4-ol. Yield = 65%. 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 8.8 Hz, 2H), 7.68 (dd, J = 17.4, 8.7 Hz, 4H), 7.44 (d, J = 8.7 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 1.86–1.62 (m, 2H), 1.36–1.16 (m, 24H), 0.88 (t, J = 6.7 Hz, 3H). MS-ESI m/z = 531.24 [M-H]−</p><!><p>Synthesized with Benzo[d][1,3]dioxol-5-ol. Yield = 62%. 1H NMR (400 MHz, CDCl3) δ 6.87–6.65 (m, 3H), 6.02 (s, 2H), 2.41 (t, J = 7.4 Hz, 2H), 1.67–1.62 (m, 2H), 1.25 (br-s, 24H), 0.88 (t, J = 5.9 Hz, 3H). MS-ESI m/z = 454.32 [M-H]−</p><!><p>Synthesized with quinolin-6-ol. Yield = 21%. 1H NMR (400 MHz, DMSO) δ 8.88 (dd, J = 4.2, 1.7 Hz, 1H), 8.38 (dd, J = 8.4, 1.6 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.79 (d, J = 2.6 Hz, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.54 (dd, J = 8.3, 4.2 Hz, 1H), 2.07 (t, J = 7.3 Hz, 2H), 1.40 (p, J = 7.1 Hz, 2H), 1.33–1.06 (m, 24H), 0.86 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 461.30 [M-H]−</p><!><p>Synthesized with 6-hydroxybenzofuran-3(2H)-one. Yield = 2%. 1H NMR (400 MHz, DMSO) δ 8.25 (br-s, 1H), 8.06 (s, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.58 (d, J = 1.7 Hz, 1H), 7.28 (dd, J = 8.6, 1.9 Hz, 1H), 2.20 (t, J = 7.1 Hz, 2H), 1.50–1.41 (m, 2H), 1.31–1.13 (m, 24H), 0.86 (t, J = 6.8 Hz, 3H). MS-ESI m/z = 545.23 [M-H]−</p><!><p>To a solution of the desired carboxylic acid (1eq) in anhydrous DCM containing 2 drops of DMF was added oxalyl chloride (1eq) at 0°C. The mixture was stirred at 0°C for 15mins and then at room temperature for 30mins. The solution was then added to a mixture of DMAP (0.1eq), triethylamine (3eq) and either 4-methoxyphenyl sulfamate (1eq) (22–23) or Phenyl sulfamate (24–28) in anhydrous DCM/DMF (1:1). After stirring overnight, the reaction mixture was extracted with 2.5% HCl, H2O and brine and dried with Na2SO4. The organic layer was evaporated under vacuum and the crude mixture separated by column chromatography as described above.</p><!><p>Synthesized with Myristic acid. Yield = 61%. 1H NMR (400 MHz, CDCl3) δ 7.78 (br, 1H), 7.20 (d, J = 9.1 Hz, 2H), 6.89 (d, J = 9.1 Hz, 2H), 3.81 (s, 3H), 2.40 (t, J = 7.5 Hz, 2H), 1.69–1.59 (m, 2H), 1.26 (br-s, 20H), 0.88 (t, J = 6.7 Hz, 3H). MS-ESI m/z = 412.25 [M-H]−</p><!><p>Synthesized with undec-10-enoic acid. Yield = (62%). 1H NMR (400 MHz, CDCl3) δ 7.23–7.16 (m, 2H), 6.90 (dd, J = 2.12, 7.01 Hz, 2H), 5.81 (ddt, J = 6.66, 10.24, 16.89 Hz, 1H), 5.08–4.82 (m, 2H), 3.81 (s, 3H), 2.54–2.33 (m, 2H), 2.04 (q, J = 6.74 Hz, 2H), 1.77–1.46 (m, 5H), 1.46–1.11 (m, 12H). MS-ESI m/z = 367.94 [M-H]−</p><!><p>Synthesized with 11-phenylundecanoic acid. Yield = 31%. 1H NMR (400 MHz, CDCl3) δ 7.43–7.32 (m, 2H), 7.32–7.20 (m, 5H), 7.19–7.11 (m, 3H), 2.78–2.15 (m, 3H), 1.72–1.39 (m, 5H), 1.17 (dd, J = 14.56, 42.81 Hz, 8H), 0.94–0.65 (m, 2H). MS-ESI m/z = 416.22 [M-H]−</p><!><p>Synthesized with 8-phenyloctanoic acid. Yield = 40%. 1H NMR (400 MHz, CDCl3) δ 7.42–7.35 (m, 2H), 7.35–7.29 (m, 1H), 7.29–7.26 (m, 4H), 7.20–7.12 (m, 3H), 2.58 (td, J = 8.0, 3.6 Hz, 2H), 2.34 (td, J = 7.6, 3.0 Hz, 2H), 1.59 (br-s, 4H), 1.29 (br-s, 6H). MS-ESI m/z = 374.09 [M-H]−</p><!><p>Synthesized with 7-phenylheptanoic acid. Yield = 64%. 1H NMR (400 MHz, CDCl3) δ 7.45–7.37 (m, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.28 (d, J = 5.4 Hz, 3H), 7.17 (t, J = 8.2 Hz, 3H), 2.59 (t, J = 7.7 Hz, 2H), 2.34 (dt, J = 15.2, 7.5 Hz, 2H), 1.62 (q, J = 8.5, 7.9 Hz, 4H), 1.34 (dq, J = 7.3, 4.4, 3.6 Hz, 4H). MS-ESI m/z = 360.13 [M-H]−</p><!><p>Synthesized with 6-phenylhexanoic acid. Yield = 74%. 1H NMR (400 MHz, CDCl3) δ 7.39 (dt, J = 8.1, 4.1 Hz, 2H), 7.35–7.30 (m, 2H), 7.30–7.26 (m, 3H), 7.16 (t, J = 6.0 Hz, 3H), 2.59 (t, J = 7.5 Hz, 2H), 2.43–2.23 (m, 2H), 1.62 (dq, J = 14.8, 7.5 Hz, 4H), 1.46–1.28 (m, 2H). MS-ESI m/z = 346.11 [M-H]−</p><!><p>Synthesized with 4-phenylcinnamic acid. Yield = 11%. 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 15.6 Hz, 1H), 7.63–7.60 (m, 6H), 7.46 (q, J = 8.3, 7.8 Hz, 2H), 7.39 (t, J = 6.7 Hz, 3H), 7.37–7.30 (m, 3H), 6.56 (d, J = 15.6 Hz, 1H). MS-ESI m/z = 378.13 [M-H]−</p><!><p>PlsY is an intrinsic membrane protein and was expressed and assayed in a native membrane environment. E. coli strain FB23281 (ΔplsY) was used as the host for plasmids expressing either the S. aureus PlsY (SA1187) or B. anthracis PlsY1 (BAS3399). B. anthracis has 3 PlsY homologs, and PlsY1 was the most similar to the single prototypical single PlsY proteins expressed in Gram-positive bacteria. Membranes were purified and acyltransferase activity was measured as described previously.5 Briefly, the reaction buffer (pH 7.4) contained 100 mM Tris–HCl, 150 mM NaCl, 1 mg/mL BSA, 5 mM Na3VO4, 100 µM [U-14C]glycerol-PO4 (8 mCi/mmol), inhibitor (200 µM) and 4 µg purified membranes. 16:0-PO4 (final concentration 100 µM) was added to start the reaction. Reactions were terminated after incubation at 37°C for 20 min by aliquotting the reaction mixture (20 µL) onto a Whatman 3 mm cellulose filter disc. Filter discs were washed in 10%, 5%, and 1% ice-cold trichloroacetic acid (20 min, 20 mL/disk) to remove unreacted glycerol-PO4 prior to scintillation counting.</p><!><p>The MIC of each test compound was determined by the microbroth dilution method in Mueller-Hinton (MH) media according to the Clinical Laboratory Standards Institute (CLSI) document M7A7 for testing of the antibiotic susceptibility of aerobic bacteria. For growth of S. pneumoniae and S. pyogenes, MH broth was supplemented with 5% lysed horse blood from BD Diagnostic Systems (Loveton Circle, Sparks, MD, USA). All test compounds were dissolved in DMSO at a concentration of 10 mg/mL and stored at −80°C. Twofold serial dilutions of test compound were prepared in MH broth in 96-well plates to give drug concentrations that ranged from 400–0.025 µg/mL. Bacterial inoculums were prepared by streaking at −80°C stock bacterial culture onto an MH agar plate, which was incubated overnight at 37°C. A single colony is picked into 10ml of MH broth and incubated in 37°C shaking incubator. The culture is grown to mid-log phase (OD600 =0.5) and then diluted to OD600 =0.001. An aliquot of culture (100 µL) was then added to each well of the 96-well plate to give an OD600 =0.0005, which corresponded to about 105 CFU/mL, and final antibiotic concentrations that ranged from 200– 0.0125 µg/mL. The 96-well plates were incubated overnight at 37°C, and the MIC was recorded as the lowest concentration of drug that inhibited 90% of visible bacterial growth. The MIC for B. anthracis was determined as previously described.15, 16</p><!><p>[14C]Acetate incorporation experiments were conducted to measure lipid metabolism activity in S. aureus or B. anthracis. For both bacteria, the culture was grown overnight and the starter culture was back diluted to an initial OD600 of 0.1 and grown until OD600 of 0.5. The culture was split into 10 mL aliquots and each aliquot was incubated with the appropriate concentration of inhibitors or DMSO (control) for 15 minutes and the OD600 of the culture was collected. [14C]Acetate (10 µCi) was added to each aliquot for 30 minutes. The cells are harvested by centrifugation and washed 4 times with phosphate-buffered saline. Pelleted cells are then lysed to harvest for lipids using the method of Bligh and Dyer17. The radioactivity from the lipid extraction was counted on a LS6500 Multipurpose Scintillation Counter and normalized to the OD600 of the cell culture. All measurements were made in duplicate and the averages with standard error were reported. The radioactive lipid extract was also separated on Silica Gel G layers developed with CHCl3:methanol:acetic acid (98:2:1) to separate the different lipid species. The radioactivity of the plate was counted using the Bioscan imaging system.</p><!><p>The method for protein, DNA, and RNA pathway labeling was similar to acetate labeling experiments. Cells were grown to OD600 of 0.5 before being split to 10 mL aliquots and incubated with appropriate inhibitors for 15 minutes. Then, either a 3H-labled amino acid mix (10 µCi) for protein pathway metabolism, [3H]thymidine (10 µCi) for DNA pathway metabolism, or [3H]uracil (10 µCi) for stable RNA synthesis was added to the culture and grown for 30 minutes. The labeled cells are then collected via vacuum filtration through 0.45 µm HA filters, and the radioactivity was counted and normalized to the OD600 of the culture. The cell density adjusted activity of the metabolic pathways from cells treated with inhibitor is divided by the metabolic activity of the untreated cells to determine the effect of the inhibitor on the metabolic pathways. Duplicated measures were made with averages and standard error were reported.</p><!><p>Cultures of S. aureus RN4220 cells were grown to OD600 = 0.5, and then split into 50 mL aliquots. Appropriate concentrations of inhibitors were added to the aliquots and grown at 37°C for 30 min and the OD600 was collected. Cells were harvested, extracted and immunoblotted to determine the ACP species as described previously.10 The amount of supernatant loaded is adjusted to OD600 such that a similar amount of total protein is loaded for each drug treated sample.</p><!><p>S. aureus was grown in Luria-Bertani broth at 37°C with rigorous shaking (225 rpm). Cells (250 mL) were grown to OD600 of 0.5, aliquoted to 50 mL cultures, and treated with no inhibitor, 25 µM, or 50 µM of 25 for 2.5 hours. Cells were washed with PBS and harvested for lipids using the method of Bligh and Dyer.17 Gas chromatography was performed on S. aureus strain RN4220 as described.10 The PtdGro molecular species were also analyzed by mass spectrometry as described previously.10</p><!><p>This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p>